Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Blue Door Therapeutics Paving the Way to Treat the Opioid Epidemic with $2 Million Dollar Treatment Center in North Scottsdale
  • USA - English


News provided by

Serendipit Consulting

May 04, 2017, 10:00 ET

Share this article

Share toX

Share this article

Share toX

Unlike other treatment centers, Blue Door is the first treatment center in the world to combine the use of cannabis with traditional, naturopathic and alternative medicine to reduce opioid use
Unlike other treatment centers, Blue Door is the first treatment center in the world to combine the use of cannabis with traditional, naturopathic and alternative medicine to reduce opioid use

SCOTTSDALE, Ariz. (PRWEB) May 04, 2017 -- Blue Door Therapeutics, the first opioid outpatient treatment center to combine the use of medical cannabis with traditional medicine, alternative and naturopathic therapeutics as an exit strategy for dependence on pain pills (opioids), is now open in North Scottsdale.

“Medical cannabis is the real game-changer for opiate dependence treatment and our team is committed to utilizing medical cannabis as another tool to improve outcomes for our opioid dependent patients,” said Dr. Ravi Chandiramani

Post this

Created by a team of board-certified physicians, Blue Door Therapeutics is focused on treating those affected by the first medically-derived epidemic in history using a combination of traditional and alternative medicine. Blue Door is the first treatment center in the world to combine the use of medical cannabis along with traditional medicine as an exit strategy for opiate use disorder.

“The opioid epidemic is at an all time high. Drug overdose is now the leading cause of accidental death in the United States, with Arizona placing in the top 10 for opioid distribution. Our team is committed to creating a customized exit strategy for each patient by using a combination of therapies to decrease opioid dependency,” said Dr. Gina Mecagni Berman, MD, CEO and co-founder of Blue Door Therapeutics. “As the first treatment center in the world to combine the use of medical cannabis with traditional, naturopathic and alternative medicine, I am excited to bring our forward-thinking approach to patients in need.”

Blue Door Therapeutics offers traditional medication-assisted treatment, using Buprenorphine/Suboxone when appropriate and individualized counseling to help patients combat withdrawal symptoms. The treatment center also offers evidence-based naturopathic treatments focusing on patient sleep habits, nutrition, comprehensive hormonal analysis and more to optimize patients to be able to heal themselves. Alternative therapies such as acupuncture, meditation and exercise are also used to heal the mind, body and spirit while developing healthy coping skills. Physician-monitored cannabis treatment utilizes cannabis to treat withdrawal symptoms and help combat cravings. Blue Door uses cannabis by not trading one drug out for another but as an exit strategy so patients can ultimately be freed from having to take any medication.

“At Blue Door, we don’t view cannabis as an illicit substance; we view it as a medical treatment that makes a lot of sense when you understand the underlying neuropharmacology between opioids and cannabinoids", said Dr. Ravi Chandiramani, medical director and co-founder of Blue Door Therapeutics. “Medical cannabis is the real game-changer for opiate dependence treatment and our team is committed to utilizing medical cannabis as another tool to improve outcomes for our opioid dependent patients.”

Blue Door Therapeutics raised more than $2 million dollars in private placement funding to launch the clinic. The opiate treatment center is already on a successful path for fast, continuous growth looking to add two more clinics in Arizona in two years, creating 10-20 jobs per clinic. The company is backed by three highly regarded board-certified physicians and a seasoned entrepreneur with a strong track record in growing small companies into large ones.

  • Dr. Frank Lovecchio, DO, MPH, FACEP and Medical Director of Blue Door Therapeutics boasts over two decades of treating patients with substance use disorders. Dr. Lovecchio has served as the Medical Director of a Poison Control Center and is a professor and research scholar at the University of Arizona College of Medicine. He is board certified in addiction medicine, medical toxicology, emergency medicine, and medical forensics. Dr. Lovecchio's focus at the clinic will be on research analyzing the success rates of using cannabis for the treatment of opioid withdrawal and cravings versus traditional therapies.
  • Dr. Gina Mecagni Berman, MD, CEO and co-founder of Blue Door Therapeutics, brings an esteemed career in both Addiction and Emergency Medicine to the treatment center. Dr. Berman practiced Emergency Medicine for ten years in Phoenix before transitioning to being the Medical Director of two medical cannabis dispensaries in Phoenix and Mesa. It was while seeing patients in the dispensary that Dr. Berman realized the benefits her patients were seeing in using cannabis to reduce or eliminate opioids.
  • Dr. Ravi Chandiramani, ND, Medical Director and co-founder of Blue Door Therapeutics, brings a wealth of knowledge to the treatment center with over 10 years of practicing both traditional and naturopathic medicine to treat addiction. Dr. Chandiramani’s holistic approach to the treatment of substance use disorders has been refined over a decade of direct clinical experience with over 1,000 patients. Over the course of his career in addiction medicine, he has served as Medical Director for several organizations providing a range of specialty services including residential treatment, partial hospitalization and intensive outpatient treatment and private inpatient detox.
  • Jason Doolittle, President of Blue Door Therapeutics, is a budding entrepreneur and three-time Inc. 500 senior sales and operations executive. Doolittle most recently served as the CEO of Base Commerce, where he led the company to place 60th on the 2015 Inc. 500 list for Fastest Growing Private Companies, ranking #1 in Arizona. Previously, he served as the Chief Sales Officer of Entrust Bankcard, President of Walnut Creek Realty and Sales Director of Skyline Financial Corp. Doolittle specializes in organization development, operations, business process re-engineering, turnaround management and financial operations.

Blue Door Therapeutics offers affordable treatment plans that vary depending on the patient’s needs. The process includes an initial visit and free consultation with the physicians to develop a treatment plan. The holistic healthcare clinic accepts insurance and is licensed by the Arizona Department of Health.

Blue Door Therapeutics is temporarily located at 10900 North Scottsdale Rd, Suite 609, in Scottsdale. Blue Door’s permanent location will open in North Scottsdale in Fall 2017. For more information, please call 602-361-3868 or visit http://www.bluedoor.org.

About Blue Door Therapeutics
Blue Door Therapeutics is an outpatient opioid treatment center that combines the use of medical cannabis with traditional medicine, alternative and naturopathic therapeutics as an exit strategy for opioid dependency. Unlike other treatment centers, Blue Door is the first treatment center in the world to combine the use of cannabis with traditional, naturopathic and alternative medicine to reduce opioid use. Composed of board-certified physicians specifically trained to transition patients off opioids, the Blue Door team is committed to treating those affected by the first medically-derived epidemic in history. Founded in 2017 and based in Scottsdale, Ariz., Blue Door Therapeutics is currently accepting new patients. For more information, please call 602-361-3868 or visit http://www.bluedoor.org.

###

Melissa DiGianfilippo, Serendipit Consulting, http://www.serendipitconsulting.com, +1 480-250-4315, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.